Lymphatic Targeting of Flubendazole via Long-Chain Fatty Acid Nanoemulsion: Pharmacokinetic Evidence of Chylomicron-Mediated Uptake in Rats.
FLZ-NE enhances flubendazole absorption via lymphatic transport in rats, suggesting potential for improved delivery in lymphatic or metastatic conditions.
Where it sits
this study against the rest of the zenagamtide corpusSummary and findings
This study evaluated the pharmacokinetics of a flubendazole nanoemulsion (FLZ-NE) in rats, focusing on lymphatic uptake. FLZ-NE showed higher systemic exposure compared to FLZ-NE with chylomicron blockade. The findings suggest that FLZ-NE relies on lymphatic transport for absorption.
Abstract
Flubendazole (FLZ), a benzimidazole anthelmintic with emerging anticancer potential, exhibits poor aqueous solubility, limited oral bioavailability, and negligible spontaneous lymphatic transport. Building on previous work in which a Maisine CC-based FLZ nanoemulsion (FLZ-NE) was developed and shown to prevent the formation of malignant wounds in a murine model, this study provides a mechanistic pharmacokinetic evaluation of its intestinal lymphatic uptake. We investigated FLZ disposition in rats after oral administration of FLZ-NE, with or without cycloheximide pretreatment (FLZ-NE/b) to inhibit chylomicron secretion. Plasma FLZ concentrations were quantified by a validated HPLC-UV method, and concentration-time data were analyzed by two-way ANOVA and noncompartmental analysis. FLZ-NE produced higher systemic exposure (C_max = 2.42 ± 0.34 μg/mL; T_max = 4 h; AUC_0 - t = 15.92 ± 3.78 μg.h/mL) than FLZ-NE/b (C_max = 0.58 ± 0.13 μg/mL; T_max = 2 h; AUC_0 - t = 4.42 ± 1.55 μg.h/mL), corresponding to a 76% reduction in C_max and a 72% reduction in AUC_0 - t under chylomicron blockade. These data indicate that FLZ-NE relies predominantly on intestinal lymphatic transport, in line with the notion that long-chain fatty acid-based, nanoscale formulations can favor chylomicron-mediated uptake. By demonstrating in vivo that this nanoemulsion drives FLZ absorption through a lymphatic component, our findings extend the earlier efficacy-focused malignant wound study with mechanistic pharmacokinetic evidence of lymphatic targeting and support nanoemulsion-based delivery as a rational strategy to improve oral absorption and expand the therapeutic potential of FLZ for lymphatic or metastatic diseases.
Background
Flubendazole is a benzimidazole anthelmintic with potential anticancer properties, but it suffers from poor solubility and bioavailability. Previous studies have developed a nanoemulsion to improve its delivery, particularly targeting lymphatic transport. This study aims to provide pharmacokinetic evidence of lymphatic uptake in a rat model, which could enhance its therapeutic utility for lymphatic or metastatic diseases.
Methods
The study used a rat model to assess the pharmacokinetics of orally administered FLZ-NE, with and without cycloheximide pretreatment to inhibit chylomicron secretion. Plasma concentrations were measured using HPLC-UV, and data were analyzed using two-way ANOVA and noncompartmental analysis. The primary outcomes were C_max, T_max, and AUC_0 - t.
Results
FLZ-NE resulted in a C_max of 2.42 ± 0.34 μg/mL and an AUC_0 - t of 15.92 ± 3.78 μg.h/mL, significantly higher than FLZ-NE/b, which had a C_max of 0.58 ± 0.13 μg/mL and an AUC_0 - t of 4.42 ± 1.55 μg.h/mL. The chylomicron blockade led to a 76% reduction in C_max and a 72% reduction in AUC_0 - t, indicating reliance on lymphatic transport.
Interpretation
The study provides mechanistic insights into the lymphatic uptake of FLZ-NE, supporting the use of nanoemulsions for enhancing oral absorption. While the results are promising, they are limited to a rat model, and the clinical significance in humans remains to be established. The findings align with previous efficacy studies but require further validation in clinical settings.
Key findings
- C_max = 2.42 ± 0.34 μg/mL for FLZ-NE
- T_max = 4 h for FLZ-NE
- AUC_0 - t = 15.92 ± 3.78 μg.h/mL for FLZ-NE
- C_max = 0.58 ± 0.13 μg/mL for FLZ-NE/b
- AUC_0 - t = 4.42 ± 1.55 μg.h/mL for FLZ-NE/b
- 76% reduction in C_max with chylomicron blockade
Limitations
- rat model only, no human data
- focus on pharmacokinetics, not efficacy
- short-term study design
- chylomicron blockade as a surrogate endpoint